The Dermatology Digest

FEBRUARY 27, 2024

Pelage Pharmaceuticals has closed a $16.75 million Series A financing led by GV with participation from Main Street Advisors, Visionary Ventures and YK BioVentures to advance a first-in-class treatment for androgenetic alopecia and other types of alopecia including chemotherapy-induced hair loss.

Pharmaceutical 36

Pharmaceutical Treatments Hospital Clinic 36

Lipgloss and Aftershave

NOVEMBER 15, 2024

By incorporating one microneedling treatment every three months and supporting it with 3 – 4 nano infusion treatments in between, while using topicals with potent ingredients and a proven delivery system professionals provide a comprehensive treatment that delivers visible, long-lasting age management results.

Management 40

Management Microneedling Therapy Pharmaceutical 40

The Dermatology Digest

FEBRUARY 26, 2024

Shared-decision making focused on weighing risks versus benefits is key when choosing the most appropriate systemic atopic dermatitis (AD) treatment for a patient, according to new research presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, DC. some of the JAK inhibitors).

Treatments 74

Treatments Dermatitis Pharmaceutical Clinic 74

The Dermatology Digest

DECEMBER 27, 2024

Johnson & Johnson has entered into an exclusive licensing agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD), from Kaken Pharmaceutical.

Dermatitis 36

Dermatitis Portfolios Pharmaceutical Innovations 36

The Dermatology Digest

AUGUST 8, 2024

Both drugs are manufactured by the pharmaceutical company Bristol Myers Squibb, which sponsored the CheckMate-915 trial, and provided the patient specimens and data used in the analysis. The post Distinct Pattern in Protein Production May Predict Severe Side Effects From Melanoma Treatment appeared first on The Dermatology Digest.

Treatments 74

Treatments Pharmaceutical Therapy Dermatology 74

The Dermatology Digest

JANUARY 23, 2024

LEO Pharma now owns TMB-001 as well as certain other assets from Timber Pharmaceuticals following its chapter 11 bankruptcy filing. All employees of Timber Pharmaceuticals will transition to LEO Pharma’s offices in New Jersey, US, the Company reports. The TMB-001 project continues as planned and without changes within LEO Pharma.

Pharmaceutical 36

Pharmaceutical Office Ingredients Therapy 36

Alison Bladh

JANUARY 21, 2025

Current Pharmaceutical Design , 17(8), pp.754768. Anti-inflammatory activity of extra virgin olive oil polyphenols: which role in the prevention and treatment of immune-mediated inflammatory diseases? New England Journal of Medicine , 368(14), pp.12791290. DOI: 10.1056/NEJMoa1200303. Russell, A. and Keast, R., Fernndez-Real, J.M.,

Diet 97

Diet Pharmaceutical Marketing Management 97

The Dermatology Digest

NOVEMBER 30, 2024

Several new therapies are coming down the pike for the treatment of lichen planus, a chronic inflammatory condition that affects an estimated 1% to 2% of the global population, according to a new report from Research and Markets. Similarly, Incyte and AFYX Therapeutics are developing new therapeutics for lichen planus.

Pharmaceutical 36

Pharmaceutical Safety Marketing Therapy 36

The Dermatology Digest

MARCH 26, 2024

Verrica Pharmaceuticals Inc.’s is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients aged 2 and older. The post Verrica Pharmaceuticals’ YCANTH Receives New Chemical Entity Status, Orange Book Listing From FDA appeared first on The Dermatology Digest.

Pharmaceutical 36

Pharmaceutical Portfolios Office Marketing 36

Renee Rouleau

JANUARY 19, 2024

Pharmaceutical and Medical Advancements Ingredients that have been traditionally used for non-skincare purposes are now finding their way into the beauty industry. Even Botox, popular in the modern day for smoothing fine lines and plumping the skin, was first used as a treatment for Parkinson’s.

Skincare 195

Skincare Innovations Ingredients Esthetician 195

The Dermatology Digest

APRIL 3, 2024

Ligand Pharmaceuticals is launching Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and has appointed Scott Plesha as Chief Executive Officer to accelerate the commercialization of berdazimer topical gel, 10.3% (Zelsuvmi) for the treatment of molluscum contagiosum. Watch Now: Nanette B. in September 2023.

Pharmaceutical 36

Pharmaceutical Sales Office Partnerships 36

Lipgloss and Aftershave

FEBRUARY 21, 2025

This article will explore the key developments in the use of dermal fillers, including the trend of dissolving fillers, an emphasis on skin quality, the rise of combination treatments, and my personal experiences with innovative treatment protocols in my clinic.

Facials 52

Facials Hydration Injections Innovations 52

The Dermatology Digest

MARCH 10, 2025

Tildrakizumab-asmn (Ilumya, Sun Pharmaceutical Industries, Inc.) ” The safety profile was consistent with the known safety profile of tildrakizumab, and no serious adverse events related to ILUMYA treatment occurred in this clinical trial,the study showed.

Pharmaceutical 36

Pharmaceutical Safety Clinic Injections 36

The Dermatology Digest

NOVEMBER 6, 2024

Alicia Edwards from Howard University College of Medicine will conduct a remote project titled, “ Investigating the Prevalence of Inborn Errors of Immunity and Treatment Responses in Pediatric Alopecia Areata: A Multi-Site Study ” under the mentorship of Leslie Castelo-Soccio, MD, PhD at National Institutes of Health.

Pharmaceutical 36

Pharmaceutical Hospital Dermatology Medical 36

The Dermatology Digest

JANUARY 8, 2025

topical ET-02 may be more effective than existing treatments for androgenic alopecia, according to results of a first-in-man clinical trial. A final assessment of the subjects was made one week after the treatments ended. Eirion Therapeutics Inc.s Key results of the study showed: Safety: ET-02 was found to be safe and well tolerated.

Safety 36

Safety Clinic Pharmaceutical Treatments 36

The Dermatology Digest

MARCH 28, 2025

Quoin Pharmaceuticals has filed a U.S. There are currently no FDA approved treatments for either Netherton Syndrome or Peeling Skin Syndrome. patent application for novel topical formulations to treat several skin diseases, including Netherton Syndrome (NS).

Pharmaceutical 36

Pharmaceutical Clinic Hospital Office 36

The Dermatology Digest

JANUARY 29, 2024

The Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-Code (J7354) for Verrica’s YCANTH, a molluscum contagiosum treatment. Medicaid and Medicare patient populations,” says Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, in a news release. “In

Pharmaceutical 74

Pharmaceutical Office Medical Management 74

The Dermatology Digest

MAY 2, 2024

The studies may also explain the long-lasting inhibition of disease severity biomarkers, such as blood thymus and activation-regulated chemokine ( TARC ) , observed after the end of the eblasakimab treatment period in earlier clinical studies.

Pharmaceutical 74

Pharmaceutical Dermatitis Office Clinic 74

The Dermatology Digest

DECEMBER 30, 2024

The 20th Annual SOCS Scientific Symposium was generously supported by the following sponsors: AbbVie, Johnson & Johnson, Sanofi and Regeneron Pharmaceuticals, Inc. Taylor, a dermatologist in Philadelphia, PA. Champion); Bristol Myers Squibb, Eli Lilly, Inc., ” This award program is supported by Bristol Myers Squibb and Pfizer.

Webinar 78

Webinar Education Social Media Dermatology 78

The Dermatology Digest

MAY 15, 2024

Verrica Pharmaceuticals Inc. has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. Torii) to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH (cantharidin) for the treatment of common warts. With a prevalence of approximately 22 million patients in the U.S.

Pharmaceutical 36

Pharmaceutical Clinic Sales Dermatology 36

The Dermatology Digest

AUGUST 21, 2024

Food and Drug Administration, according to Leo Pharma and Timber Pharmaceuticals. The trial did not show a statistically significant difference between the proportion of patients treated with TMB-001 responding to treatment after 12 weeks compared with patients treated with vehicle.

Pharmaceutical 36

Pharmaceutical Clinic Office Dermatology 36

The Dermatology Digest

MARCH 10, 2024

Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC, discusses the need for a comprehensive treatment approach for CHE.

Treatments 36

Treatments Pharmaceutical Dermatitis Eczema 36

The Dermatology Digest

FEBRUARY 5, 2024

Food and Drug Administration has expanded the indication for dupilumab (Dupixent, Sanofi, Regeneron Pharmaceuticals, Inc.) for the treatment eosinophilic esophagitis in pediatric patients aged 1 to 11 years who weigh at least 15 kg.

Eczema 74

Eczema Pharmaceutical Management Diet 74

Aesthetics Advisor

FEBRUARY 11, 2024

Millions of people suffer for years or decades without treatment because insurance companies don’t approve screening for autoimmunity until the patient shows significant signs of organ or tissue destruction. At this point, the patient can be prescribed some type of immune-suppressing treatment.

Pharmaceutical 67

Pharmaceutical Diet Clinic Management 67

The Dermatology Digest

JANUARY 2, 2024

discussed treatment options, the study showed. featured the pharmaceutical industry. Most YouTube videos about melanoma were presented by physicians (41.5%). When analyzed by content, 43.6% featured general information about melanoma; 29.8% discussed risk factors; 29.8% discussed prognosis; and 38.3% In all, 28.7%

Pharmaceutical 69

Pharmaceutical Education Dermatology Clinic 69

The Dermatology Digest

OCTOBER 26, 2024

Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. Both groups had similar proportions of patients with treatment-emergent adverse events (TEAEs).

Dermatitis 36

Dermatitis Treatments Pharmaceutical Eczema 36

The Dermatology Digest

MARCH 13, 2024

Adam Friedman, MD, Professor and Chair of Dermatology at George Washington School of Medicine and Health Sciences in Washington, DC, shares his excitement about chronic spontaneous urticaria (CSU) treatments coming down the pike including remibrutinib, Novartis’ investigational oral Bruton’s tyrosine kinase inhibitor.

Treatments 36

Treatments Dermatitis Dermatology Eczema 36

The Dermatology Digest

MARCH 10, 2024

Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC, discusses the need for a comprehensive treatment approach for CHE. Topical isotretinoin, even when applied to 90% of a patient’s body surface area, showed minimal systemic absorption.

Treatments 36

Treatments Dermatitis Eczema Dermatology 36

Dermatology Times

OCTOBER 17, 2023

Hilary Baldwin, MD, offers her insights and hypotheses regarding the future of over-the-counter and pharmaceutical treatments, emphasizing the evolving landscape and the potential role of targeted microbiome-based approaches in the management of acne.

Pharmaceutical 36

Pharmaceutical Skincare Management Treatments 36

Dermatology Times

DECEMBER 18, 2023

Emphasizing the challenges of the steroid treatment cycle, the expert provides insights into integrating parental preferences for "natural" agents alongside effective pharmaceutical options.

Pharmaceutical 36

Pharmaceutical Management Treatments 36

The Dermatology Digest

MARCH 11, 2024

Adding narrowband ultraviolet B phototherapy to treatment with ritlecitinib (Litfulo, Pfizer) in vitiligo may improve patient outcomes.

Dermatitis 69

Dermatitis Eczema Dermatology Pharmaceutical 69

The Dermatology Digest

APRIL 11, 2024

The first patient has been treated in Stamford Pharmaceuticals Inc.’s Vismodegib is a hedgehog Pathway inhibitor (HHPI) that is approved for the treatment of adult patients presenting with locally advanced and metastatic basal cell carcinoma.

Pharmaceutical 36

Pharmaceutical Clinic Injections Dermatology 36

The Dermatology Digest

JANUARY 5, 2024

Food and Drug Administration (FDA) has approved Zelsuvmi (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum in adults and children one year of age and older. Zelsuvmi is expected to be commercially available during the second half of 2024, according to Ligand Pharmaceuticals. in September 2023.

Pharmaceutical 36

Pharmaceutical Office Medical Dermatology 36

Aesthetics Advisor

AUGUST 16, 2023

a drug developer working on a treatment similar to Novo’s Wegovy, jumped 12%. Novo traded at fresh highs as the Danish pharmaceutical company gained ground on the only European megacap that is larger than it. Makers of syringes for the pharmaceutical industry, Stevanato Group SpA and West Pharmaceutical Services Inc.,

Sales 36

Sales Pharmaceutical Marketing Medical 36

The Dermatology Digest

FEBRUARY 16, 2024

The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy.

Pharmaceutical 36

Pharmaceutical Safety Dermatitis Therapy 36

The Dermatology Digest

JANUARY 5, 2024

The last patient has been dosed in Part 2 of Verrica Pharmaceuticals Inc.’s s Phase 2 trial of VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. VP-315 is a chemotherapeutic administered intratumorally.

Pharmaceutical 36

Pharmaceutical Safety Office Clinic 36

The Dermatology Digest

JANUARY 4, 2024

Ustekinumab is approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. As a global subsidiary of Intas Pharmaceuticals, Accord BioPharma will be responsible for U.S. commercialization. In October of 2023, Accord BioPharma reached a settlement with Janssen Biotech Inc.,

Pharmaceutical 36

Pharmaceutical Partnerships Clinic Safety 36